1571 related articles for article (PubMed ID: 17108138)
21. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
22. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M; Hombach AA; Abken H
Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
[TBL] [Abstract][Full Text] [Related]
23. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
24. Adoptive cellular immunotherapy with CD19-specific T cells.
Rössig C; Pscherer S; Landmeier S; Altvater B; Jürgens H; Vormoor J
Klin Padiatr; 2005; 217(6):351-6. PubMed ID: 16307422
[TBL] [Abstract][Full Text] [Related]
25. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
26. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities.
Shiao SL; McNiff JM; Masunaga T; Tamura K; Kubo K; Pober JS
Transplantation; 2007 Feb; 83(3):304-13. PubMed ID: 17297405
[TBL] [Abstract][Full Text] [Related]
28. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
Cheadle EJ; Hawkins RE; Batha H; Rothwell DG; Ashton G; Gilham DE
J Immunother; 2009 Apr; 32(3):207-18. PubMed ID: 19242379
[TBL] [Abstract][Full Text] [Related]
29. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors.
Alvarez-Vallina L; Hawkins RE
Eur J Immunol; 1996 Oct; 26(10):2304-9. PubMed ID: 8898938
[TBL] [Abstract][Full Text] [Related]
30. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
Koehler H; Kofler D; Hombach A; Abken H
Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
[TBL] [Abstract][Full Text] [Related]
31. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.
Zhao Z; Condomines M; van der Stegen SJC; Perna F; Kloss CC; Gunset G; Plotkin J; Sadelain M
Cancer Cell; 2015 Oct; 28(4):415-428. PubMed ID: 26461090
[TBL] [Abstract][Full Text] [Related]
32. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA
Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098
[TBL] [Abstract][Full Text] [Related]
33. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
34. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.
Singh NP; Yolcu ES; Taylor DD; Gercel-Taylor C; Metzinger DS; Dreisbach SK; Shirwan H
Cancer Res; 2003 Jul; 63(14):4067-73. PubMed ID: 12874008
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
36. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Brentjens RJ; Santos E; Nikhamin Y; Yeh R; Matsushita M; La Perle K; Quintás-Cardama A; Larson SM; Sadelain M
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5426-35. PubMed ID: 17855649
[TBL] [Abstract][Full Text] [Related]
37. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
[TBL] [Abstract][Full Text] [Related]
38. A CD2/CD28 chimeric receptor triggers the CD28 signaling pathway in CTLL.2 cells.
Feldhaus AL; Evans L; Sutherland RA; Jones LA
Gene Ther; 1997 Aug; 4(8):833-8. PubMed ID: 9338012
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
40. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]